SCHEMBL18612934

SCHEMBL18612934

C=Nc1nc(Nc2c(C)cccc2[N+](=O)[O-])ncc1/C=C(\C)c1cc(OC)cc(OC)c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ FGFR4 P22455 7/20 0.41
▸ RPS6KB2 Q9UBS0 1/20 0.37
▸ BTK Q06187 1/20 0.35
▸ CYP19A1 P11511 1/20 0.34
▸ MAPT P10636 2/20 0.34
▸ MEN1 O00255 1/20 0.34
▸ POLB P06746 1/20 0.34
▸ MAPK1 P28482 1/20 0.34
▸ KMT2A Q03164 1/20 0.34
▸ SMN1; SMN2 Q16637 1/20 0.34
▸ JAK2 O60674 1/20 0.34
▸ FGFR1 P11362 3/20 0.33
▸ PLK1 P53350 2/20 0.33
▸ PIN1 Q13526 1/20 0.33
▸ ALDH1A1 P00352 1/20 0.33
▸ PTK2 Q05397 1/20 0.33
▸ CYP1A2 P05177 1/20 0.33
▸ CSF1R P07333 1/20 0.33
▸ CYP3A4 P08684 1/20 0.33
▸ CYP2D6 P10635 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20706002 0.85 FGFR4 (0.42) FGFR4FGFR1CYP1A2CSF1RCYP3A4
SCHEMBL20706003 0.82 FGFR4 (0.63) FGFR4FGFR1CYP1A2CSF1RCYP3A4
SCHEMBL15412876 0.72 FGFR4 (0.49) FGFR4RPS6KB2BTKFGFR1PIN1
SCHEMBL15413168 0.72 FGFR4 (0.60) FGFR4RPS6KB2CYP19A1MAPTMEN1
SCHEMBL21756590 0.70 CYP19A1 (0.37) FGFR4CYP19A1MAPTMEN1POLB
SCHEMBL21756596 0.70 CYP19A1 (0.41) FGFR4CYP19A1MAPTMEN1POLB
SCHEMBL20705997 0.69 FGFR4 (0.44) FGFR4FGFR1CYP1A2CSF1RCYP3A4
SCHEMBL21756616 0.69 JAK2 (0.38) FGFR4MAPTMEN1MAPK1KMT2A
SCHEMBL18612968 0.68 FGFR4 (0.45) FGFR4RPS6KB2MAPTMEN1MAPK1
SCHEMBL22089989 0.68 PTK2 (0.39) FGFR4MAPTMEN1MAPK1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170066812-A1 INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR BLUEPRINT MEDICINES CORPORATION 2017-03-09 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170066812-A1 INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR FGFR1, FGFR2, FGFR3 FGFR4 5/4885RPS6KB2 370/4885BTK 93/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback